s0122170
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- PROTEIN_SECRETION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ALLOGRAFT_REJECTION+0.300
- MTORC1_SIGNALING+0.300
- MYC_TARGETS_V1+0.300
- MYC_TARGETS_V2+0.300
- APICAL_SURFACE+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.400
- ANGIOGENESIS-0.200
- HEDGEHOG_SIGNALING-0.200
- NOTCH_SIGNALING-0.200
- UV_RESPONSE_DN-0.200
- APICAL_JUNCTION-0.100
- BILE_ACID_METABOLISM-0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.100
- HYPOXIA-0.100
- MYOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696807 | — | — | 0.843 |
| 2 | TCGA-AR-A0TW-01A-11R-A084-07 | — | B | 0.809 |
| 3 | C3N-03764 | — | cohortA1 | 0.805 |
| 4 | TCGA-A8-A09I-01A-22R-A034-07 | — | C | 0.804 |
| 5 | ERR2208906 | — | — | 0.801 |
| 6 | c340b651-bd01-4194-a67b-e801d0feeb2b | — | — | 0.793 |
| 7 | TCGA-CV-6938-01A-11R-1915-07 | — | — | 0.791 |
| 8 | BS_GJNCYABP | ATRT | — | 0.787 |
| 9 | TCGA-A8-A08P-01A-11R-A00Z-07 | — | C | 0.784 |
| 10 | TCGA-A2-A0SW-01A-11R-A084-07 | — | C | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |